GLOSSARY continued FDA Food and Drug Administration
ITT Intent-To-Treat
FH Familial Hypercholesterolemia
IV Intravenous
FLT3 FMS-Like Tyrosine Kinase-3
JIA Juvenile Idiopathic Arthritis
G-CSF Granulocyte Colony Stimulating Factor
LDL Low-Density Lipoprotein
GI Gastrointestinal
LDL-C Low-Density Lipoprotein Cholesterol
GIST Gastrointestinal Stromal Tumor
mAb Monoclonal Antibody
GLP-1RA Glucagon-Like Peptide-1 Receptor Agonist
MACE Major Adverse Cardiovascular Events
GM-CSF Granulocyte-Macrophage Colony Stimulating Factor
MADRS Montgomery – Åsberg Depression Rating Scale
GVHD Graft Versus Host Disease H Half HAART Highly Active Antiretroviral Therapy HAM-D Hamilton Depression Rating Scale HAP Healthcare-Associated Pneumonia Hb Hemoglobin HbA1c Hemoglobin A1c HCC Hepatocellular Carcinoma HCP Healthcare Professional HCV Hepatitis C Virus
MAOI Monoamine Oxidase Inhibitor MDD Major Depressive Disorder MDI Metered Dose Inhaler MRI Magnetic Resonance Imaging MRSA Methicillin-Resistant Staphylococcus Aureus MS Multiple Sclerosis N/A Not Applicable NASH Non-Alcoholic Steatohepatitis NDA New Drug Application NHL Non-Hodgkin Lymphoma
HER Human Epidermal Growth Factor Receptor
NIAID National Institute of Allergy and Infectious Diseases
HER2 Human Epidermal Growth Factor Receptor 2
NSAID Non-Steroidal Anti-Inflammatory Drug
HFA Hydrofluoroalkane
NSCLC Non-Small Cell Lung Cancer
HIT Heparin Induced Thrombocytopenia
ODT Orally Disintegrating Tablet
HIV Human Immunodeficiency Virus
OR Odds Ratio
HIV-1 Human Immunodeficiency Virus-1
ORR Overall/Objective Response Rate
HR Hazard Ratio
OS Overall Survival
HSCT Hematopoietic Stem Cell Transplant
OTC Over-the-Counter
HTN Hypertension
PAH Pulmonary Arterial Hypertension
IBS Irritable Bowel Syndrome
PARP Poly(ADP-ribose) polymerase
IBS-C Irritable Bowel Syndrome, Constipation Predominant
PASI Psoriasis Area and Severity Index
IGA Investigator's Global Assessment IM Intramuscular ITP Immune Thrombocytopenic Purpura
45 | MAGELLANRX.COM
PASI 50 Psoriasis Area and Severity Index 50% PASI 70 Psoriasis Area and Severity Index 70% PASI 90 Psoriasis Area and Severity Index 90% PASI 100 Psoriasis Area and Severity Index 100%